GHENT, Belgium, 7 January 2013 - Ablynx [Euronext Brussels: ABLX] today announces it will present at the 31(st) Annual J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, 10(th) January 2013 at 12:00 p.m. PST (21:00 p.m. CET). The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx. The presentation will provide an update on the Company's late-stage proprietary Nanobody® programmes, the Company's growth and partnering strategy and the outlook for the near term future. The presentation will be webcast live and can be accessed on the day via the Ablynx website at www.ablynx.com. A replay of the webcast will be available on the Company's website for 30 days following the presentation. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast. About Ablynx Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies(®), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com. For more information, please contact Ablynx: Dr Edwin Moses Chairman and CEO t:   +32 (0)9 262 00 07 m: +44 (0)7771 954 193 /      +32 (0)473 39 50 68 e:  edwin.moses@ablynx.com Marieke Vermeersch Associate Director Investor Relations t:   +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e:  marieke.vermeersch@ablynx.com Follow us on Twitter @AblynxABLX M:Communications: Mary-Jane Elliott, Amber Bielecka, Claire Dickinson t:   +44 207 920 2330 e:  ablynx@mcomgroup.com press release in pdf format: http://hugin.info/137912/R/1668728/541899.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Ablynx via Thomson Reuters ONE [HUG#1668728]